Navigation Links
Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection

imilar potency for neutralizing anthrax toxin in vitro as was seen with serum obtained from subjects who had been vaccinated with anthrax vaccine.

About Anthrax

According to the Centers for Disease Control and Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease was contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing problems and shock. Inhalation anthrax is often fatal, even with the use of antibiotics.

About PharmAthene, Inc.

PharmAthene, a privately-held biotechnology company, was formed to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia(R) for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit www.PharmAthene.com.

About Medarex, Inc.

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing exper
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Cethromycin Shown Effective Against Anthrax in Study
3. Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection
4. Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
5. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
6. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models
9. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial

Post Your Comments:
(Date:11/25/2009)...inker.comannouncesthatanewmarketresearchreportisav...t-AGlobalMarketPerspective ,, http://www.rep...lobal-Market-Perspective.html ,, Risinginciden...nationsisaprincipalfactorinfluencinggrowthinthemam...eastcancerhasallowedwomentocomeforwardfortheiryear...
(Date:11/25/2009)...e/--SwissrayInternational,Inc.aleadingmanufacturer...todaythatitsoperationshavebeenacquiredbyaprivateSw...,smedicalimagingbrand.Theacquisitionincludedallass...entory.After25yearsofsuccessandgrowthSwissrayisnow...ntswithstableandsteadygrowth. ,, "Swissrayhaslo...
(Date:11/25/2009)...l/--NuVasive,Inc.(Nasdaq: NUVA ),amedicaldevicecom...ivesurgicaltreatmentsforthespine,announcedtodaytha...,at5:30p.m.ET/2:30p.m.PT.Theconferencecallwillfocu...ny,sproductsandwillincludecommentsfrommanagementfo...umbersare1-877-407-4018fordomesticcallersand1-201-...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Swissray International Announces New Ownership 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 1OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 2OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 3OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 4OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 5LA BioMed study finds higher survival rate among intoxicated trauma patients 58613 1Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 1Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 2Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 3Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 4
...teria to Help Facilitate EHR Adoption in Small, Am..., March 3 The Certification Commission for Heal...rally recognized body for testing and certifying e...will develop dermatology-specific functionality cr... in part a response to an application from the Ame...
...IS, March 3 Novexel, a speciality pharmaceutical,...f novel antibiotics,designed to overcome the signi...unces today that its most advanced injectable anti... beta lactamase inhibitor, NXL104, with the,well e...has entered a second,Phase II clinical trial. , ...
Other Medicine Technology:Certification Commission for Healthcare Information Technology to Develop Dermatology-Specific Functionality Criteria for Electronic Health Record (EHR) Technology 2Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 2Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 3Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 4
(Date:11/26/2009)... No more letters from the North Po...lized text messages from Santa , ...increase operational efficiencies at the North Pol... keep children all over the globe informed of his ... Santa’s research department have identified...
(Date:11/25/2009)...DINA,Minn.,Nov.25/PRNewswire-USNewswire/--Whenmost...tachiropractorcanalsogivepatientsthehelptheyneed.T...eyourjaw(mandible)contacts/connectswithyourskull(t...dwithTMJdysfunctionarepainwithchewing,clickingorpo...MJdysfunctionincluding:headaches,fatigue,sleepdist...
(Date:11/25/2009)...ONGBEACH,Calif.,Nov.25/PRNewswire/--Thanksgivingme...iorsinthegreaterLongBeachareathankstoFaithInAction...denceatHome(IAH),adivisionofSCANHealthPlan.Formore...fvolunteerstodeliverwarmThanksgivingmealstoseniors...thLosAngelesandsurroundingcities. ,, "Ourwarmho...
(Date:11/25/2009)...rm survivors of testicular cancer who were treated... side effects, including neurological side effects... treated with chemotherapy, according to a new stu... the National Cancer Institute . , Marianne Bryd...University Hospital, in Bergen, Norway, and collea...
(Date:11/25/2009)..., already used to fight rheumatoid arthritis, coul... , WEDNESDAY, Nov. 25 (HealthDay News) -- A...a and rheumatoid arthritis now also shows some pro... 1 diabetes. , The drug, rituximab (Rituxan), h...sulin, even though the disease had destroyed some ...
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
...egory Laslo will travel to Washington, D.C., Sunda...t with congressional leaders and gain their suppor...earch toward a cure for epilepsy. , , Rundlett, 1...th support from Abbott. The program rallies young ...
... Phoenix, AZ, will travel to Washington, D.C., Su...meet with congressional leaders and gain their sup...research toward a cure for epilepsy. , , McArthur...nd funded by Abbott Laboratories. The program rall...
...use from intimate partners spent 42 percent more o...rding to a long-term study of more than 3,000 wome... The study revealed that women who suffered physic...cal and emotional pain it causes, domestic violenc...
...ces, Inc. announced today that it has provided $19...spital in Mountain View, California. The five-year...y of Siemens Medical Solutions equipment which wil...e than 40 years, El Camino Hospital has been servi...
...ty, IA will travel to Washington, D.C., Sunday, Ma...h congressional leaders and gain their support for... toward a cure for epilepsy. , , Carlson, 16, is ... by Abbott Laboratories. The program rallies young...
...Inc., the premier cancer diagnostics company and t...ay announced the appointment of Grady Barnes, Ph.D...o Fujirebio Diagnostics with 25 years of diagnosti...dian Bioscience. , , As Chief Scientific Officer,...
Other Medicine News:Health News:Maryland Youths Share Epilepsy Message on Capitol Hill 2Health News:Arizona Youth Shares Epilepsy Message on Capitol Hill 2Health News:Physical abuse raises women's health costs over 40 percent 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 3Health News:Iowa Youth Shares Epilepsy Message on Capitol Hill 2Health News:Fujirebio Diagnostics Appoints Grady Barnes as Chief Scientific Officer 2
USA Series MICRO-6L Semi-Rigid Ureteroscope
...he ACMI DUR-8 Elite's 8.7 Fr shaft reaches into th...iding complete intrarenal access, even reaching th... covering and working channel ease insertion of bo...stable shaft construction, tight-bend radius tip, ...
...he ACMI USA Series DUR-8 Durable Flexible Ureteros...e entire intrarenal collecting system with little ... secondary deflection allow complete intrarenal ac...ction facilitates access to the proximal ureter an...
S-Series Cystourethroscope Standard Obturator
Medicine Products: